Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 569

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Open access
Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., Rini, Brian · 2020 · Cancer Cell

Abstract

Summary Integrated multi-omics evaluation of 823 tumors from advanced renal cell carcinoma (RCC) patients identifies molecular subsets associated with differential clinical outcomes to angiogenesis blockade alone or with a checkpoint inhibitor. Unsupervised transcriptomic analysis reveals seven molecular subsets with distinct angiogenesis, immune, cell cycle, metabolism, and stromal programs. While sunitinib and atezolizumab+bevacizumab are effective in subsets with high angiogenesis, atezolizumab+bevacizumab improves clinical benefit in tumors with high T-effector and/or cell cycle transcription. Somatic mutations in PBRM1 and KDM5C associate with high angiogenesis and AMPK/Fatty acid oxidation gene expression, while CDKN2A/B and TP53 alterations associate with elevated cell cycle and anabolic metabolism. Sarcomatoid tumors exhibit lower prevalence of PBRM1 mutations and angiogenesis markers, frequent CDKN2A/B alterations, and increased PD-L1 expression. These findings can be applied to molecularly stratify patients, explain improved outcomes of sarcomatoid tumors to checkpoint blockade vs. anti-angiogenics alone, and develop personalized therapies in RCC and other indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.10.011

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 569

Metadata

Authors
Motzer, R. J., Banchereau, R., Hamidi, H., Powles, T., McDermott, D., Atkins, M. B., Escudier, B., Liu, L.-F., Leng, N., Abbas, A. R., Fan, J., Koeppen, H., Lin, J., Carroll, S., Hashimoto, K., Mariathasan, S., Green, M., Tayama, D., Hegde, P. S., Schiff, C., Huseni, M. A., & Rini, B.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2020-12
Volume
38
Issue
6
Pages
803-817.e4
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3096713247
Cited by
569
References
62
FWCI
34.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. https://app.cochat.ai/papers/10.1016/j.ccell.2020.10.011
The paper
Motzer, R. J., Banchereau, R., Hamidi, H., Powles, T., McDermott, D., Atkins, M. B., Escudier, B., Liu, L.-F., Leng, N., Abbas, A. R., Fan, J., Koeppen, H., Lin, J., Carroll, S., Hashimoto, K., Mariathasan, S., Green, M., Tayama, D., Hegde, P. S., . . . Rini, B. (2020). Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.10.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.